<DOC>
	<DOC>NCT02694536</DOC>
	<brief_summary>This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic pancreatic cancer.</brief_summary>
	<brief_title>A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma with locally advanced, unresectable, or metastatic disease No prior systemic treatment for metastatic disease Adjuvant therapy ≥6 months prior to study entry with no residual toxic effects Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3 Life expectancy ≥12 weeks Adequate hematologic, hepatic, and renal function Negative pregnancy test within 72 hours of study drug and use of effective contraception among women of childbearing potential Unstable systemic disease Prior systemic human epidermal growth factor receptor 1 (HER1) or epidermal growth factor receptor (EGFR) inhibitors Other malignancy within 5 years prior to study entry Significant opthalmologic abnormality Inability to take oral medication Need for IV alimentation Prior surgery affecting absorption Active peptic ulcer disease Nursing mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>